Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

215
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
215
Block Diagram Reduction01:22

Block Diagram Reduction

574
The process of deriving the transfer function of a control system often involves reducing its block diagram to a single block. This simplification can be achieved through a series of strategic operations, including relocating branch points and comparators. These operations preserve the overall function of the system while allowing for easier manipulation and combination of blocks.
The first step in this process is the identification and relocation of a branch point. A branch point, where a...
574
Elements of Block Diagrams01:25

Elements of Block Diagrams

732
Block diagrams serve as a visual representation of the input-output relationships within a system. An illustrative example is a heating system, where the set temperature activates the furnace to warm the room to the desired level. Block diagrams are versatile, modeling linear systems through Laplace transform variables and nonlinear systems using time domain variables.
A block diagram typically includes essential elements such as comparators, blocks, and feedback loops. Each of these elements...
732
Relation between Mathematical Equations and Block Diagrams01:20

Relation between Mathematical Equations and Block Diagrams

3.5K
In a spring-mass-damper system, the second-order differential equation describes the dynamic behavior of the system. When transformed into the Laplace domain under zero initial conditions, this equation can be effectively analyzed and manipulated. The transformation into the Laplace domain converts differential equations into algebraic equations, simplifying the process of isolating the output.
3.5K
Implicit Differentiation01:25

Implicit Differentiation

72
In classical mechanics, motion is often described through relationships between spatial coordinates and time. A car moving along a straight highway with constant acceleration serves as a simple case where velocity is an explicit function of time. This scenario results in a linear equation, enabling straightforward analysis using basic differentiation techniques.In contrast, a satellite in circular orbit follows a path defined by an implicit function. The position of the satellite is constrained...
72
Logarithmic Differentiation01:28

Logarithmic Differentiation

76
When a car’s weight and driving forces act on a tire, they impose an external load on the rubber material. This load is resisted internally by forces distributed throughout the tire structure, which are defined as stress. The resulting deformation of the rubber due to this stress is quantified as strain. The relationship between stress and strain governs how the tire deforms under load and is central to understanding its mechanical response during operation.Rubber exhibits a nonlinear...
76

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Journal of hematology & oncology·2026
Same author

Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).

Lancet regional health. Americas·2026
Same author

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.

The Journal of allergy and clinical immunology·2026
Same author

A pharmacological profile of pacritinib for the treatment of myelofibrosis.

Expert review of clinical pharmacology·2026

Related Experiment Video

Updated: Feb 13, 2026

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.7K

ORY-1001: Overcoming the Differentiation Block in AML.

Prithviraj Bose1, Marina Y Konopleva1

  • 1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Cancer Cell
|March 14, 2018
PubMed
Summary

Maes and colleagues investigated ORY-1001, a potent small-molecule inhibitor targeting lysine-specific demethylase 1 (LSD1), for acute myeloid leukemia (AML). Findings from in vitro, in vivo, and patient data support its potential therapeutic role in AML.

More Related Videos

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
13:21

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples

Published on: May 4, 2012

16.3K
A Novel Approach to Overcome Movement Artifact When Using a Laser Speckle Contrast Imaging System for Alternating Speeds of Blood Microcirculation
07:20

A Novel Approach to Overcome Movement Artifact When Using a Laser Speckle Contrast Imaging System for Alternating Speeds of Blood Microcirculation

Published on: August 30, 2017

8.8K

Related Experiment Videos

Last Updated: Feb 13, 2026

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
11:17

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays

Published on: June 13, 2019

7.7K
Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
13:21

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples

Published on: May 4, 2012

16.3K
A Novel Approach to Overcome Movement Artifact When Using a Laser Speckle Contrast Imaging System for Alternating Speeds of Blood Microcirculation
07:20

A Novel Approach to Overcome Movement Artifact When Using a Laser Speckle Contrast Imaging System for Alternating Speeds of Blood Microcirculation

Published on: August 30, 2017

8.8K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Acute myeloid leukemia (AML) remains a challenging hematologic malignancy with unmet therapeutic needs.
  • Lysine-specific demethylase 1 (LSD1) is implicated in AML pathogenesis and represents a potential therapeutic target.
  • Small-molecule inhibitors offer targeted approaches for cancer therapy.

Purpose of the Study:

  • To evaluate the efficacy and mechanism of ORY-1001, a novel LSD1 inhibitor, in preclinical models of AML.
  • To assess the safety and tolerability of ORY-1001 in patients with AML.
  • To explore potential biomarkers for response to ORY-1001 therapy.

Main Methods:

  • In vitro studies using AML cell lines to assess cytotoxicity and target engagement.
  • In vivo studies in murine models of AML to evaluate anti-leukemic activity.
  • Correlative analysis of clinical data from two AML patients treated with ORY-1001.

Main Results:

  • ORY-1001 demonstrated potent and selective inhibition of LSD1 activity in vitro.
  • Preclinical studies showed significant anti-leukemic effects of ORY-1001.
  • Preliminary patient data suggested a favorable safety profile and potential clinical activity.

Conclusions:

  • ORY-1001 is a promising oral, selective LSD1 inhibitor with demonstrated preclinical efficacy in AML.
  • Further clinical investigation of ORY-1001 in AML is warranted.
  • LSD1 inhibition represents a viable therapeutic strategy for AML.